BUSINESS COMBINATION (Details Narrative) - USD ($) |
9 Months Ended | |||||
|---|---|---|---|---|---|---|
Mar. 04, 2025 |
Sep. 30, 2026 |
Jul. 06, 2026 |
Feb. 15, 2026 |
Dec. 31, 2025 |
Jul. 29, 2025 |
|
| BUSINESS COMBINATION | ||||||
| Sellers retention description | amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of LUCEMYRA® and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of LUCEMYRA | |||||
| Common stock shares issued for acquisition | 500,000 | 500,000 | ||||
| Closing market price | $ 0.31 | |||||
| Common stock price per share | $ 0.31 | $ 0.001 | $ 0.36 | $ 0.34 | $ 0.001 | |
| Common stock purchased | 500,000 | |||||
| Exercise price | $ 1.00 | $ 0.35 | ||||
| Fair value of stock issued | $ 153,500 | |||||
| Royalty payments | $ 108,260 | |||||
| Upfront purchase price | $ 400,000 | $ 392,441 | ||||
| Discounted at the risk-free rate | 4.04% | |||||
| Discounted at required metric risk premium | 24.09% |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount the entity has committed to make for future royalty guarantees. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|